Bladder Cancer Weekly

November 18, 2024

Videos

Peer-to-Peer Clinical Conversations

JCOG1019 Trial Examines Watchful Waiting vs BCG for High-Grade T1 Bladder Cancer - Hiroshi Kitamura

Hiroshi Kitamura

Zachary Klaassen interviews Hiroshi Kitamura about the JCOG1019 study, examining watchful waiting versus BCG therapy in high-grade T1 bladder cancer patients with no residual tumor after second TUR.

View

Harnessing Artificial Intelligence in Bladder Cancer: Digital Tools for Enhanced Diagnosis and Treatment - David McConkey

David McConkey

David McConkey discusses the application of artificial intelligence (AI) in bladder cancer research, focusing on AI pathology.

View

Beyond the Abstracts

Histopathological, Molecular and Clinical Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder (LELC-B) - Beyond the Abstract

Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials - Beyond the Abstract

Conference Coverage

ASTRO 2024: Role of Surgery in the Management of Genitourinary Small Cell Tumors

ASTRO 2024: Radiation Therapy for Small Cell Bladder Cancers

ASTRO 2024: Pathologic Features of Small Cell Variants of the Genitourinary Tract

ASTRO 2024: Pembrolizumab Monotherapy Following Tri-Modality Treatment for Selected Patients with Muscle-Invasive Bladder Cancer

ASTRO 2024: Bi-Institutional Safety Analysis of Combining Radiotherapy and Enfortumab Vedotin in Advanced Urothelial Cancer

Physician-Scientist Review Articles

The Effect of GLP1R Agonists on Bladder, Kidney, and Prostate Cancer Risk - Expert Commentary

Digital Spatial Profiling in Muscle-Invasive Bladder Cancer - Expert Commentary

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Reduced p63 expression is linked to unfavourable prognosis in muscle-invasive urothelial carcinoma of the bladder.

Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study.

"I was in a very deep, dark place... I wasn't prepared for that": A qualitative assessment of the emotional well-being needs of patients undergoing cystectomy.

Biomarkers of treatment response in bladder cancer.

Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis.

Diagnostic significance of peritumoral enhancement in distinguishing between muscle-invasive and non-muscle-invasive bladder cancer.

An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial.

Induction Avelumab Followed by Chemoimmunotherapy and Maintenance Versus Chemotherapy Alone as First-Line Therapy in Cis-Ineligible Metastatic Urothelial Carcinoma (INDUCOMAIN): A Randomized Phase II Study

Oncological outcomes of organ-sparing cystectomy versus standard radical cystectomy in male patients diagnosed with bladder cancer.

Outcomes after robot-assisted radical cystectomy with orthotopic neobladder in women.

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer.

Distant recurrence of non-muscle invasive bladder cancer 8 years after initial treatment.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login